| Reference | <p>
<span style="font-size:12px;"><span style="font-family:arial,helvetica,sans-serif;">1.</span></span><span style="color: rgb(51, 51, 51); font-family: openSans, arial, sans-serif; font-size: 14px; font-variant-ligatures: normal; orphans: 2; widows: 2;"><span style="font-size:12px;"><span style="font-family:arial,helvetica,sans-serif;">Barter, P.J.: Arterioscler. Thromb. Vasc. Biol., 25, 1095 (2005)</span></span></span></p>
<div>
2. Expert Opin Pharmacother. 2012 Apr;13(5):717-22. doi: 10.1517/14656566.2012.658774. Epub 2012 Mar 9.Fenofibric acid for hyperlipidemia.Saurav A(1), Kaushik M, Mohiuddin SM.</div>
<div>
</div>
<div>
INTRODUCTION: 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (i.e.statins) are the mainstay of therapy for hyperlipidemia, as per the current National Cholesterol Education Program (NCEP) recommendation. However, the role of other agents, such as the fibrates, is continually being debated in the context of incremental risk reduction, especially in the setting of mixed dyslipidemia. Results from the ACCORD Trial have further added to the confusion. Fibrates also have a role to play in familial hyperlipidemias and in hypertriglyceridemia. Fenofibric acid is one of the newly approved forms of fenofibrate with enhanced bioavailability and was recently approved by the Food </div>
<div>
and Drug Administation (FDA) for the treatment of various types of hyperlipidemia, in conjunction with statins.</div>
<div>
AREAS COVERED: This article reviews the role of fenofibric acid in the context of results from recent randomized trials on fenofibrate, including the ACCORD Trial. It discusses the current status of fenofibric acid in the management of dyslipidemia, especially in combination with statins, and also addresses the comparative efficacy and safety profile of this new molecule against other agents in its class.</div>
<div>
EXPERT OPINION: Fenofibric acid in combination with low- to moderate-dose statins is an effective and safe option in the treatment of mixed dyslipidemia, although the long-term effects on cardiovascular risk reduction need to be explored further.</div>
<div>
</div>
<div>
3. Acta Crystallogr C. 2005 Feb;61(Pt 2):o81-4. doi: 10.1107/S0108270104032573. Epub 2005 Jan 15.Fenofibric acid.Rath NP(1), Haq W, Balendiran GK.</div>
<div>
</div>
<div>
Unlike the related fenofibrate molecule [Henry, Zhang, Gao & Bruckner (2003). Acta Cryst. E59, o699-o700], fenofibric acid {systematic name: 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid}, C17H15ClO4, contains a carboxylic acid moiety instead of an ester moiety. This polar moiety plays an important role in the formation of a rare acid-to-ketone hydrogen-bond-type packing interaction. The lack of an isopropyl group in fenofibric acid aligns the carboxyl group on the same side as the ketone carbonyl group; this conformation may play an important role in discrimination between the acid and </div>
<div>
the fenofibrate molecule in molecular recognition.</div>
<p>
</p>
<div>
</div>
|
